Table 1.

Clinicopathological characteristics of all patients

		Training cohort N=249		Validation cohort N=124
		AGCa	PMGCb	AGC	PMGC
N		161	88	85	39
Age (min-max)		59.71 (33-83)	60.51 (27-87)	59.84 (31-83)	57.87 (38-81)
Gender (male/female)		119/42	55/33	67/18	24/15
Tumor location	Upper 1/3	25	8	10	5
	Middle 1/3	45	30	28	13
	Lower 1/3	70	33	36	10
	Mixed	16	13	10	9
	Data Absent	5	4	1	2
Differentiation	High + Moderate	28	28	16	8
	Poor	125	43	67	23
	Data Absent	8	17	2	8
Lauren classification	Intestinal	37	8	22	2
	Diffuse	44	15	18	4
	Mixed	50	6	29	9
	Data Absent	30	59	16	24
CEA	Mean (Min-Max)	8.48 (0.4-94.9)	9.11 (0.5-209.5)	14.94 (0.4-1.9)	16.40 (0.5-372.8)
	<5ng/mL	88	42	55	18
	≥5ng/mL	38	21	14	12
	Data Absent	35	25	16	9
CA19-9	Mean (Min-Max)	140.95 (1-8982)	237.01 (1-5682)	23.38 (1.5-170.9)	428.02 (4.8-4210)
	<37U/mL	94	38	49	12
	≥37U/mL	23	25	11	16
	Data Absent	44	25	25	11
CA125	Mean (Min-Max)	20.95 (5.5-225.3)	52.89 (4-281.2)	31.76 (5.6-401.3)	46.94 (9-246)
	<35U/mL	86	34	46	14
	≥35U/mL	13	22	7	8
	Data Absent	62	32	32	17
CA72-4	Mean (Min-Max)	16.73 (0.6-300)	43.58 (0.8-300)	18.97 (0.35-257.3)	30.23 (1-300)
	<10U/mL	70	24	39	14
	≥10U/mL	19	28	15	6
	Data Absent	72	36	31	19

^aAGC: Advanced gastric cancer; ^bPMGC: Peritoneal metastasis gastric cancer.